Dermatomyositis severity in children and adults
Part of Bones, joints & muscles, Brain & nervous system, Skin clinical trials.
This study looks at how severe dermatomyositis is in people who develop it as children or adults. It aims to better understand the disease and may help guide future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of dermatomyositis based on medical guidelines from 2017.
- You cannot have had any cancer within 3 years before or after your dermatomyositis diagnosis.
- You must not have antisynthetase syndrome, which is a different but related autoimmune condition.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at a type of skin inflammation called panniculitis that can happen in people with dermatomyositis. The goal is to learn more about this condition so that better treatments can be developed.
This research study helps doctors better understand myositis—a group of rare diseases that cause muscle inflammation and weakness. Researchers collect blood samples, medical history, and sometimes muscle biopsies to learn more about what causes these conditions and how to treat them better.
This study looks at how well skin symptoms improve in adults with cutaneous dermatomyositis by using a specific skin-scoring tool. The results may help doctors better measure treatment response and guide care.
This study looks at what makes dermatomyositis more severe in people of Caribbean background living in Guadeloupe. By understanding these factors, doctors may better manage this rare muscle and skin disease.
This study looks for environmental risk factors that may be linked to anti-synthetase syndrome, a type of inflammatory muscle disease. It compares people with the condition to carefully matched people without it, using questionnaires, blood samples, and lung imaging when needed.
This Phase 3 study tests whether interleukin-2 can better control “active” dermatomyositis, an inflammatory muscle and skin disease. Participants will be monitored to see if treatment improves disease activity and symptoms.
Hear when a new Dermatomyositis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.